HRAS and cancer: Notably, Liu's group demonstrated that combining BSO with the NADPH oxidase inhibitor DPI effectively kills cancer cells with HRAS G12V and KRAS mutations, suggesting a promising dual-targeting strategy for RAS-driven cancers [73].